Open Nav

FBM Therapeutics

  • Gordon Foulkes, FBM Therapeutics

Identify VCs for Series A or pharmaceutical partners

  • Date:Thursday, October 18
  • Time:2:15 PM - 2:30 PM
  • Room:Elizabethan A
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:The company focus is new therapeutics for dermal fibrosis. To date, there are two lead compounds in pre-clinical development. We are seeking $10M to move the first 2 programs through to IND. The first drug candidate, FBM5712, was originally discovered and nominated for clinical development by Pfizer. FBM5712 is a small molecule NCE, and a potent inhibitor of ALK-5, the kinase domain of the TGF-B receptor. The initial clinic indications are keloid scars and scleroderma. There are no approved drugs for either indication. 8kg of API is in-hand, as are candidate clinical formulations. 7 day tox studies have been complete. The second program is an antisense oligo which targets CTGF, a downstream TGF-B pathway. The target indication is hypertrophic scarring, a multibillion market with no approved drugs and where initial clinical proof of efficacy is in-hand.
  • Company Website:Not available
  • Company HQ City:San Diego
  • Company HQ Country:United States
  • Company HQ State:California                  
  • CEO/Top Company Official:J Gordon Foulkes
  • Year Founded:2018
  • Main Therapeutic Focus:Dermatology
  • Lead Product in Development :FBM5712 a TGFB ALK-5 kinase inhibitor
  • Development Phase of Primary Product:Pre-Clinical
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :2
  • Additional Information/Comments:Over 30 years of research, and literally thousands of publications, have demonstrated the key role of TGF-β in a wide variety of fibrotic conditions. An important role for TGF-β in every tissue that becomes fibrotic in man have been reported; including the eye, heart, lung, liver, kidney and skin. The question for drugs targeting TGF-β is not “Is TGF-β important in human fibrosis?”, but whether one can achieve an acceptable therapeutic index systemically given its pleiotropic biology. FBMT’s unique approach to this challenge is to develop topically applied drugs to inhibit TGF-β for the treatment of conditions related resulting from skin fibrosis. Members of the FBMT management team, all 25+ year Industry veterans, are uniquely qualified to develop such drugs; they previously discovered and ran clinical trials with TGF-β3, have advanced kinase inhibitors into clinical trials, and and are the only group to have successfully developed an anti-scarring drug through Phase 2.
  • Previous and Current Investors:N/A
  • Size of Last Investment Round:N/A
  • Total Amount Raised to Date, In All Rounds:To date self funded by Founders
Speakers
Gordon Foulkes
FBM Therapeutics
Back